CogState signs licensing deal with Merck Canada
25 June, 2012 by Dylan Bushell-EmblingCogState (ASX:CGS) has signed the first of a planned series of licensing deals to have its tests sold to GPs for the detection of neurodegenerative conditions.
STA to bring new CDI treatment to A/NZ
22 June, 2012 by Dylan Bushell-EmblingSpecialised Therapeutics Australia (STA) has secured a deal to launch a new therapy for the colostrum difficile “superbug” in Australia and New Zealand.
Market moves: CSL buyback hits $600m
21 June, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) has now repurchased close to $600 million worth of its own shares, under a buyback program which commenced in October last year.
Mayne clears hurdle to SUBACAP approval in EU
21 June, 2012 by Dylan Bushell-EmblingMayne Pharma (ASX:MYX) is back on track to gaining marketing approval from the EMA for its SUBACAP fungal infection treatment, after its application was temporarily derailed by UK regulators.
World’s top agbiotech conference to visit Down Under
21 June, 2012 by AusBiotechThe world’s leading agricultural biotechnology event, ABIC (Agricultural Biotechnology International Conference) 2012, is coming to our region in September with the annual event to be held in Rotorua, New Zealand, and hosted by NZBIO with the support of AusBiotech.
Virus traces in Fluvax blamed for risk in children
21 June, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) unit CSL Biotherapies has tentatively blamed the particulars of the manufacturing process for the adverse reactions to its Fluvax influenza vaccine in some young children in 2010.
BIO 2012 biotech profile: Bionomics
20 June, 2012 by Dylan Bushell-EmblingBionomics recently captured headlines with its spectacular deal with Ironwood Pharmaceuticals for its anti-anxiety compound, BNC210. But the South Australian biotech has even more tricks up its sleeve.
Mesoblast insists Teva partnership is strong
19 June, 2012 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has defended the strength of its relationship with key partner Teva Pharmaceutical Industries, calling rumors that Teva is not committed to the tie-up “unfounded.”
Immuron raises $442k in undersubscribed SPP
19 June, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) has raised just over $442,000 in a share purchase plan (SPP), less than half of the $1 million target.
R&D Tax Incentive attracts MS clinical trial
19 June, 2012 by AusBiotechNew Zealand-based Innate Immunotherapeutics has announced the company will proceed with plans to conduct a Phase IIB clinical trial in Australia, after positive interim data from the company’s Phase I/II clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS).
Bionomics ends MS collaboration with Merck Serono
15 June, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) will cease collaborating with Merck Serono to develop autoimmune disorder treatments, and seek alternate partners for its Kv1.3 program.
What the Raising the Bar research exemption means for biotech
15 June, 2012 by Tim DeanThe research exemption in the new Raising the Bar bill allows experimentation on patented processes, but the line between what is permitted and what is infringing a patent is not yet fully clear.
PIC reports to Ministers on treatment of similar biologics
14 June, 2012 by AusBiotechThe Pharmaceuticals Industry Council (PIC), with members AusBiotech, Medicines Australia and the GMiA, has reported to the Federal Government on the preferred treatment of follow-on biologics for reimbursement.
ResMed launches sleep apnoea device in US
14 June, 2012 by Dylan Bushell-EmblingResMed (ASX:RMD) has brought Narval CC, an alternative treatment to PAP therapy for snoring and sleep apnoea, to the US market.
Opinion: The brutal truth about innovation in Australia
14 June, 2012 by Staff WritersDr Rowan Gilmore, CEO of the Australian Institute for Commercialisation, wonders whether Australian government and business are truly hungry enough to drive innovation in this country.
